# A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

> **NCT04992065** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 267 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** NNC0385-0434 A 15 mg
- **DRUG:** NNC0385-0434 A 40 mg
- **OTHER:** Placebo I A (for NNC0385-0434 A 15 mg)
- **DRUG:** NNC0385-0434 A 100 mg
- **OTHER:** Placebo I A (for NNC0385-0434 A 40 mg)
- **OTHER:** Placebo II A (for NNC0385-0434 A 100 mg)
- **DRUG:** Evolocumab 140 mg/mL, Repatha®

## Key facts

- **NCT ID:** NCT04992065
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-03
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-06-20
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04992065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04992065, "A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04992065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*